Brind.

Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.

4 reports, 2 independent Updated Aug 5
Gone quiet
Reports
4
Developments
4
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.

Who's involved

What this event is mainly about
Kymera TherapeuticsSanofi

How it developed

Newest first. Tap a step to see who reported it.
  1. Elizabeth Laws has been appointed to lead the KT-621 development program, which is advancing as a first-in-class oral small molecule degrader, involving Sanofi and Kymera Therapeutics.Sub-event
  2. Sanofi advances Kymera's degrader candidate.Sub-event
  3. Kymera Therapeutics and Sanofi collaborate on IRAK4 program development for an oral molecular glue degrader.1 source
  4. Kymera announces new partnership deal for CDK2 degrader and discontinues lead IRAK4 program.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GuruFocus.comKymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... Revenue: $11.5 million, attributed to the Sanofi collaboration. R&D Expenses: $78.4 million, with $8.
  • Unknown outlet
  • Unknown outlet